SYSayuri Yoshimura

Sayuri Yoshimura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sayuri Yoshimura has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adipose Tissue-Derived Mesenchymal Stem Cells Attenuate Staphylococcal Enterotoxin A-Induced Toxic Shock

    by Krisana Asano, Sayuri Yoshimura, Akio Nakane

    Adipose tissue-derived stem cells (ASCs), mesenchymal stromal cells isolated from adipose tissues, exhibit immunomodulatory effects which are promising for several applications including the therapeutics of inflammatory diseases. In the present study, the effect of ASCs on bacterial toxin-induced inflammation was investigated. Intraperitoneal administration of ASCs rescued mice from lethal shock induced by staphylococcal enterotoxin A (SEA) potentiated with lipopolysaccharide. In the serum and/or spleen of ASC-administered mice, the production of proinflammatory cytokines including interferon-gamma, tumor necrosis factor-alpha, interleukin-6 (IL-6) and IL-2 reduced. By quantitative real-time PCR, the expression of Foxp3 in the ASC-administered mice was not altered. On the other hand, the expression of IL-12 receptor and STAT4 decreased by ASC administration. These results imply that the effect of ASCs is not involved in the lineage of regulatory T cells but these cells may modulate TH1 differentiation. This information provides evidence that ASCs have effective property to attenuate SEA-induced toxic shock and would prompt further exploration on other inflammatory diseases caused by bacterial toxins or bacterial infections.


  • Open Access

    Attenuation of Collagen-Induced Arthritis in Mice by Salmon Proteoglycan

    by Sayuri Yoshimura, Krisana Asano, Akio Nakane

    Rheumatoid arthritis (RA) is a serious autoimmune disease caused by chronic inflammation of connective tissues. The basic principle of RA treatment is aimed to reduce joint inflammation. Our previous studies demonstrated that salmon cartilage proteoglycan (PG) suppresses excess inflammation in different mouse inflammatory diseases. In this study, we investigated the prophylactic effect of PG on the progression of RA using an experimental mouse model, collagen-induced arthritis (CIA). Clinical and histological severity of CIA was attenuated by daily oral administration of PG. In the joints of PG-administered mice, infiltration of macrophages and neutrophils and also osteoclast accumulation were limited. In comparison to nonadministered mice, anti-collagen antibodies in the sera of PG-administered mice did not alter. On the other hand, local expression of interleukin-17A (IL-17A), IL-6, IL-1β, interferon-γ(IFN-γ), C-C chemokine ligand 2 (CCL2), C-X-C chemokine ligand 1 (CXCL1), and CXCL2 in the joints of PG-administered mice decreased. Moreover, in the response of type II collagen- (CII-) restimulation ex vivo, IL-17A and IFN-γproduction by splenocytes from PG-administered mice was less than that of control mice. These data suggested that daily ingested PG attenuated CIA pathogenesis by modulating immune response of splenocytes to CII stimulation and local production inflammatory cytokines and chemokines in the joints.